[Ip-health] Hepatitis C Pill Rockets Gilead Into Big Leagues

Elizabeth Rajasingh elizabeth.rajasingh at keionline.org
Thu Jul 24 06:57:11 PDT 2014

Hepatitis C Pill Rockets Gilead Into Big Leagues
July 23, 2014

For decades, a liver disease that would slowly kill the infected person
didn't even have a name, let alone an effective medicine.

Now, a new pill promising to cure most cases of the disease, eventually
called hepatitis C, is believed to be the biggest new drug launch ever,
catapulting maker Gilead Sciences <http://quotes.wsj.com/GILD>Inc. into the
ranks of the top-selling pharmaceutical companies.

The pill, Sovaldi, notched $3.5 billion in second-quarter sales, Gilead
said Wednesday. As a result of its lucrative move into hepatitis C
treatment, the Foster City, Calif., company roughly doubled its revenue
guidance for the year's net product sales to $21 billion to $23 billion.

Such sales would put Gilead, once best known for its drugs treating
HIV/AIDS, on par with the total revenues of biotechnology trailblazer Amgen
<http://quotes.wsj.com/AMGN> Inc. and insulin pioneer Eli Lilly
<http://quotes.wsj.com/LLY> & Co.

As it enters the industry big leagues, Gilead is facing more public
scrutiny. Sovaldi's list price, about $1,000 a day for a 12-week course of
treatment, has drawn criticism from politicians and insurance officials who
say the health-care system can't afford such expensive treatments.

Gilead counters with the pill's effectiveness: Studies show it cures about
9 out of 10 patients, helping them avoid more costly care such as liver
transplants. The company said in a conference call with analysts and
investors that 9,000 patients have been cured by Sovaldi since it went on

Gilead said 47 state Medicaid agencies are covering the cost of Sovaldi,
albeit after authorizing its use for each patient, while the remaining
three states are deciding whether to reimburse the drug. Gilead said it is
preparing to talk with senators who have questioned the pricing.

The company has previously faced criticism from patients and insurers
regarding its pricing of HIV/AIDS treatments.

And companies including Merck, AbbVie and Roche Holding
<http://quotes.wsj.com/CH/ROG> AG  are battling Gilead over valuable patent
rights tied to Sovaldi, aiming to get a piece of that pie.Commercial
challenges also loom for Gilead. AbbVie <http://quotes.wsj.com/ABBV>
Inc., Bristol-Myers
Squibb <http://quotes.wsj.com/BMY> Co.  and Merck
<http://quotes.wsj.com/MRK> & Co. are among the companies working on new
drugs to compete with Gilead's. A rival could gain advantage, analysts say,
if it could develop treatment that works in less time than the 12 weeks
with Sovaldi currently.

Analysts estimate Sovaldi will surpass $10 billion in sales this year,
making it one of the world's biggest sellers.

Early use of the pill, which the U.S. Food and Drug Administration approved
last December, is outpacing the trajectory of the drug previously said to
have the fastest launch ever, an older hepatitis C treatment called Incivek
from Vertex Pharmaceuticals <http://quotes.wsj.com/VRTX>Inc.

Sales could go even higher if Gilead wins approval for another hepatitis C
pill, which it aims to combine with Sovaldi in the first all-oral
treatment, an easier-to-take regimen sought by patients. The company said
it saw signs that many patients were waiting for the new regimen to go on

FDA review of the second pill, ledipasvir, is "moving ahead nicely," said
Norbert Bischofberger, Gilead's research-and-development chief. The
deadline for approval is Oct. 10.

Gilead's chief operating officer, John Milligan, said he hoped insurers
"will be preparing" for a potential ledipasvir approval. He attributed some
of the insurer criticism of Sovaldi's price to high levels of use that the
plans didn't expect.

Another Gilead executive, Paul Carter, suggested the company may not price
ledipasvir as high as Sovaldi, saying the "majority of value" in its
combination with Sovaldi would be in Sovaldi. Yet other executives said it
was too early to speculate about pricing.

Gilead didn't include in its guidance sales of a new blood-cancer drug,
which the FDA approved Wednesday. Analysts estimate the pill, Zydelig, will
have about $1 billion in sales in 2017. It marks Gilead's first medicine
for cancer, another disease it's targeting.

It marks Gilead's first medicine for cancer, the third disease it's

In Gilead laboratories, "we've never had so many things going forward as we
do today, and we've never felt more confident" about their prospects, Dr.
Milligan said. Given its pipeline, he added, Gilead doesn't feel a "strong
need" to do deals to bring in new compounds. Given its pipeline, he added,
Gilead doesn't feel a "strong need" to do deals to bring in new compounds.

Gilead shares, up 53% over the past year through Wednesday's close, rose 36
cents to $90.70 in after-hours trading.

Overall for the second quarter, Gilead reported a profit of $3.66 billion,
or $2.20 a share, up from $722.6 million, or 46 cents a share, a year
earlier. Excluding items, adjusted per-share earnings rose to $2.36 from 50
cents. Excluding items, adjusted per-share earnings rose to $2.36 from 50
cents. Revenue more than doubled to $6.53 billion from $2.77 billion.

Elizabeth Rajasingh
Perl Fellow, Knowledge Ecology International
1621 Connecticut Ave. NW, Suite 500
Washington, DC 20009
*elizabeth.rajasingh at keionline.org <elizabeth.rajasingh at keionline.org>* |

More information about the Ip-health mailing list